Methyl-thiazoles: A novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in mycobacterium tuberculosis

Journal of Medicinal Chemistry

Volumn 56, Issue 21, 2013, Pages 8533-8542

  Shirude, Pravin S ^a   Madhavapeddi, Prashanti ^a   Naik, Maruti ^a   Murugan, Kannan ^a   Shinde, Vikas ^a   Nandishaiah, Radha ^a   Bhat, Jyothi ^a   Kumar, Anupriya ^a   Hameed, Shahul ^a   Holdgate, Geoffrey ^a   Davies, Gareth ^a   McMiken, Helen ^a   Hegde, Naina ^a   Ambady, Anisha ^a   Venkatraman, Janani ^a   Panda, Manoranjan ^a   Bandodkar, Balachandra ^a   Sambandamurthy, Vasan K ^a   Read, Jon A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,6 DIFLUOROBENZYL) N [5 [1 HYDROXY 1 (4 METHYLTHIAZOL 2 YL)ETHYL] 1,3,4 THIADIAZOL 2 YL] 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,6 DIFLUOROPHENYL) N [5 [1 HYDROXY 1 (4 METHYLTHIAZOL 2 YL)ETHYL] 1,3,4 THIADIAZOL 2 YL]ACETAMIDE; 1 [5 [1 (2,6 DIFLUOROBENZYL) 1H 1,2,4 TRIAZOL 3 YLAMINO] 1,3,4 THIADIAZOL 2 YL] 1 (4 METHYLTHIAZOL 2 YL)ETHANOL; 1 [5 [1 (2,6 DIFLUOROBENZYL) 1H PYRAZOL 3 YLAMINO] 1,3,4 THIADIAZOL 2 YL] 1 (4 METHYLTHIAZOL 2 YL)ETHANOL; 1 [5 [1 (2,6 DIFLUOROBENZYL) 1H PYRAZOL 4 YLAMINO] 1,3,4 THIADIAZOL 2 YL] 1 (4 METHYLTHIAZOL 2 YL)ETHANOL; 1 [5 [4 (2,6 DIFLUOROBENZYL)PYRIMIDIN 2 YLAMINO] 1,3,4 THIADIAZOL Y YL] 1 (4 METHYLTHIAZOL 2 YL)ETHANOL; 1 [5 [6 (2,6 DIFLUOROBENZYL)PYRIDIN 2 YLAMINO] 1,3,4 THIADIAZOL 2 YL] 1 (4 METHYLTHIAZOL 2 YL)ETHANOL; 1 [5 [[1 (2,6 DIFLUOROBENZYL) 1H PYRAZOYL 3 YL]AMINO] 1,3,4 THIADIAZOL 2 YL] 1 (4 METHYL 1,3 THIAZOL 2 YL)ETHANOL; 1 [5 [[5 CLYCLOPROPYL 1 (2,6 DIFLUOROBENZYL) 1H PYRAZOL 3 YL]AMINO] 1,3,4 THIADIAZOL 2 YL] 1 (4 METHYLTHIAZOL 2 YL)ETHANOL; 2 (O TOLYLOXY) 5 HEXYLPHENOL; 3 (2,6 DIFLUOROBENZYL) 5 [[5 [1 HYDROXY 1 (4 METHYLTHIAZOL 2 YL)ETHYL] 1,3,4 THIADIAZOL 2 YLAMINO]METHYL]OXAZOLIDIN 2 ONE; CYTOCHROME P450; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CELL ACTIVITY; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TARGETING; ENZYME INHIBITION; HYDROGEN BOND; ISOTHERMAL TITRATION CALORIMETRY; MELTING POINT; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; PHYSICAL CHEMISTRY; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE;

BACTERIAL PROTEINS; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 84887896126     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4012033     Document Type: Article

References (26)

1. Global Tuberculosis Control: Surveillance, Planning, Financing; World Health Organization: Geneva, Switzerland, 2011.
2. Lu, H.; Tonge, P. J. Inhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway Acc. Chem. Res. 2008, 41, 11-20
3. McDevitt, D.; Rosenberg, M. Exploiting genomics to discover new antibiotics Trends Microbiol. 2001, 9, 611-617
4. Payne, D. J.; Warren, P. V.; Holmes, D. J.; Ji, Y.; Lonsdale, J. T. Bacterial fatty-acid biosynthesis: A genomics-driven target for antibacterial drug discovery Drug Discovery Today 2001, 6, 537-544
5. Lamichhane, G. Novel targets in M. tuberculosis: search for new drugs Trends Mol. Med. 2011, 17, 25-33
6. Rawat, R.; Whitty, A.; Tonge, P. J. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 13881-13886
7. Vilcheze, C.; Jacobs, W. R. The Mechanism of Isoniazid Killing: Clarity Through the Scope of Genetics Annu. Rev. Microbiol. 2007, 61, 35-50
8. Banerjee, A.; Dubnau, E.; Quemard, A.; Balasubramanian, V.; Um, K. S.; Wilson, T.; Collins, D.; de Lisle, G.; Jacobs, W. R., Jr. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis Science 1994, 14, 227-230
9. v in vitro Bioorg. Med. Chem. Lett. 1998, 8, 843-846
10. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26
11. Hartkoorn, R. C.; Sala, C.; Neres, J.; Pojer, F.; Magnet, S.; Mukherjee, R.; Uplekar, S.; Boy-Röttger, S.; Altmann, K. H.; Cole, S. T. Towards a new tuberculosis drug: pyridomycin-nature's isoniazid EMBO Mol. Med. 2012, 4, 1032-1042
12. Rafferty, J. B.; Simon, J. W.; Baldock, C.; Artymiuk, P. J.; Baker, P. J.; Stuitje, A. R.; Slabas, A. R.; Rice, D. W. Common themes in redox chemistry emerge from the X-ray structure of oilseed rape (Brassica napus) enoyl acyl carrier protein reductase Structure 1995, 3, 927-938
13. Kuo, M. R.; Morbidoni, H. R.; Alland, D.; Sneddon, S. F.; Gourlie, B. B.; Staveski, M. M.; Leonard, M.; Gregory, J. S.; Janjigian, A. D.; Yee, C.; Musser, J. M.; Kreiswirth, B.; Iwamoto, H.; Perozzo, R.; Jacobs, W. R.; Sacchettini, J. C.; Fidock, D. A. Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data J. Biol. Chem. 2003, 278, 20851-20859
14. Pan, P.; Tonge, P. J. Targeting InhA, the FASII Enoyl-ACP Reductase: SAR Studies on Novel Inhibitor Scaffolds Curr. Top. Med. Chem. 2012, 12, 672-693
15. Ballell Pages, L.; Castro Pichel, J.; Fernandez Menendez, R.; Fernandez Velando, E. P.; Gonzalez Del Valle, S.; Mendoza Losana, A.; Wolfendale, M. J. (Pyrazol-3-yl)-1,3,4-thiadiazole-2-amine and (Pyrazol-3-yl)-1,3,4-thiazole-2- amine Compounds. PCT publication No. WO 2010/118852 A1, 2010.
16. Castro Pichel, J.; Fernandez Menendez, R.; Fernandez Velando, E. P.; Gonzalez Del Valle, S.; Mallo-Rubio, A. 3-Amino-Pyrazole Derivatives Useful Against Tuberculosis. PCT publication No. WO 2012/049161 A1, 2012.
17. Ledź, P. S.; Śledź, P.; Lang, S.; Stubbs, C. J.; Abell, C. High-Throughput Interrogation of Ligand Binding Mode Using a Fluorescence-Based Assay Angew. Chem., Int. Ed. 2012, 51, 7680-7683
18. Parikh, S. L.; Moynihan, D. P.; Xiao, G.; Tonge, P. J. Roles of Tyrosine 158 and Lysine 165 in the catalytic mechanism of InhA, the Enoyl-ACP Reductase from Mycobacterium tuberculosis Biochemistry 1999, 38, 13623-13634
19. + ratio mediates coresistance to isoniazid and ethionamide in mycobacteria Antimicrob. Agents Chemother. 2005, 49, 708-720
20. Luckner, S. R.; Liu, N.; Am Ende, C. W.; Tonge, P. J.; Kisker, C. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis J. Biol. Chem. 2010, 285, 14330-14337
21. Rozwarski, D. A.; Vilcheze, C.; Sugantino, M.; Bittman, R.; Sacchettini, J. C. Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate J. Biol. Chem. 1999, 274, 15582-15589
22. He, X.; Alian, A.; Stroud, R.; Ortiz de Montellano, P. R. Pyrrolidine Carboxamides as a Novel Class of Inhibitors of Enoyl Acyl Carrier Protein Reductase from Mycobacterium tuberculosis J. Med. Chem. 2006, 49, 6308-6323
23. Sullivan, T. J.; Truglio, J. J.; Boyne, M. E.; Novichenok, P.; Zhang, X.; Stratton, C.; Li, H. J.; Kaur, T.; Amin, A.; Johnson, F.; Slayden, R. A.; Kisker, C.; Tonge, P. J. High Affinity InhA Inhibitors with Activity against Drug-Resistant Strains of Mycobacterium tuberculosis ACS Chem. Biol. 2006, 1, 43-53
24. Chang, A.; Schiebel, J.; Yu, W.; Bommineni, G. R.; Pan, P.; Baxter, M. V.; Khanna, A.; Sotriffer, C. A.; Kisker, C.; Tonge, P. J. Rational Optimization of Drug-Target Residence Time: Insights from Inhibitor Binding to the Staphylococcus aureus FabI Enzyme-Product Complex Biochemistry 2013, 52, 4217-4228
25. Dessen, A.; Quemard, A.; Blanchard, J. S.; Jacobs, W. R., Jr.; Sacchettini, J. C. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis Science 1995, 267, 1638-1641
26. Schiebel, J.; Chang, A.; Lu, H.; Baxter, M. V.; Tonge, P. J.; Kisker, C. Staphylococcus aureus FabI: Inhibition, Substrate Recognition and Potential Implications for In Vivo Essentiality Structure 2012, 9, 802-813